TuHURA reports partial tumor responses in early Merkel cell carcinoma trial

TuHURA Biosciences announced that the first three patients in its open‑label Phase 1b/2a study of IFx‑2.0 combined with Keytruda showed partial responses by RECIST v1.1 at six months. The trial, which plans to enroll nine deep‑seated metastatic MCC patients, administers 0.1 mg IFx‑2.0 weekly for three weeks followed by Keytruda every three weeks. The company also highlighted prior data where five of eight patients achieved durable major responses lasting up to 33 months, and it is enrolling 10‑12 patients in a related deep‑seated disease cohort while advancing a randomized Phase III trial.

The early efficacy signals may reduce risk for the upcoming Phase III trial and could lift investor sentiment toward TuHURA’s immunotherapy platform, according to the company’s statements. Positive data may also support discussions with the FDA on regulatory pathways.

  • 1Three patients achieved partial responses under RECIST v1.1 criteria at the six‑month assessment.
  • 2The trial plans to initially enroll nine patients with visceral metastatic MCC.
  • 3Patients received IFx‑2.0 (0.1 mg) injected into a single tumor once weekly for three weeks.
  • 4In a prior study, five of eight patients achieved durable major anti‑tumor responses lasting an average of 23 months, with some up to 33 months.
  • 5TuHURA expects to enroll 10‑12 patients in the deep‑seated disease study, with at least eight enrolled by the first quarter.
  • 6The company is running a randomized, placebo‑controlled Phase III trial comparing IFx‑2.0 plus pembrolizumab with pembrolizumab plus placebo in frontline Stage III/IV MCC.

Sources